Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Several studies have reported that pravastatin can mitigate the progression of kidney disease, but limited evidence exists regarding its effects on kidney function in Asian patients. This multicenter prospective observational study aimed to assess the effect of pravastatin on kidney function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in clinical practice.
Methods: This 48-week prospective multicenter study included 2604 of 2997 eligible patients with dyslipidemia and T2DM who had available estimated glomerular filtration rate (eGFR) measurements. The primary endpoint was eGFR percent change at week 24 from baseline. We also assessed secondary endpoints, which included percent changes in eGFR at weeks 12 and 48 from baseline, as well as changes in eGFR, metabolic profiles (lipid and glycemic levels) at 12, 24, and 48 weeks from baseline, and safety.
Results: We noted a significant improvement in eGFR, with mean percent changes of 2.5%, 2.5%, and 3.0% at 12, 24, and 48 weeks, respectively (all adjusted p < 0.05). The eGFR percent changes significantly increased in subgroups with baseline eGFR 30-90 mL/min/1.73 m, glycated hemoglobin (HbA1c) ≥ 7 at baseline, no hypertension history, T2DM duration > 5 years, or previous statin therapy. Lipid profiles were improved and remained stable throughout the study, and interestingly, fasting glucose and HbA1c were improved at 24 weeks.
Conclusion: Our findings suggest that pravastatin may have potential benefits for improving eGFR in Korean patients with dyslipidemia and T2DM. This could make it a preferable treatment option for patients with reduced kidney function.
Trial Registration Number: NCT05107063 submitted October 27, 2021.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263229 | PMC |
| http://dx.doi.org/10.1007/s12325-024-02862-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Therapeutic advances in metabolic dysfunction-associated steatotic liver disease].
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).
View Article and Find Full Text PDFSpontaneous Aortic Sealing with Tranexamic Acid in Type A Dissection: A Novel Life-Saving Finding.
Eur J Case Rep Intern Med
August 2025
Department of Gastroenterology and Hepatology, University of Balamand, Beirut, Lebanon.
Unlabelled: Aortic dissection is a life-threatening cardiovascular emergency, particularly Stanford type A, which typically necessitates urgent surgical intervention. Despite advances in surgical techniques and perioperative care, preoperative bleeding and coagulopathy remain significant challenges. Tranexamic acid, an antifibrinolytic agent, is widely used to minimize perioperative bleeding in cardiovascular surgeries; however, its role in the non-surgical, preoperative stabilization of aortic dissection has not been well established.
View Article and Find Full Text PDFMetabolic Syndrome Is Associated with the Prognosis in Elderly Critically Ill Patients with Acute Kidney Injury.
Diabetes Metab Syndr Obes
September 2025
Department of Nephrology, Wuyi County First People's Hospital, Jinhua City, Zhejiang Province, People's Republic of China.
Purpose: Metabolic syndrome (MetS) is linked to adverse outcomes in chronic diseases, but its impact on acute kidney injury (AKI) in elderly critically ill patients remains unclear. This study aimed to evaluate the association between MetS and 90-day mortality in this population.
Patients And Methods: A retrospective analysis included 774 elderly patients (≥65 years) with AKI admitted to the ICU from January 2022 to December 2023.
Risk Factors of Subclinical Left Ventricular Systolic Dysfunction in Older Adults with Type 2 Diabetes and Preserved LVEF.
Clin Interv Aging
September 2025
Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, People's Republic of China.
Objective: This study evaluates cardiac function in older adults with T2DM and preserved LVEF using two-dimensional speckle-tracking echocardiography to explore the risk factors associated with subclinical left ventricular systolic dysfunction (GLS <18%) in this population.
Methods: All patients (n = 87, aged 60 years and above) and controls (n = 20) underwent clinical assessment and echocardiography, including GLS assessment.
Results: Univariate analysis identified gender (OR 3.
Clinical Patterns of Dyslipidemia in Patients With Initial-Treatment and Drug-Naïve Schizophrenia.
Alpha Psychiatry
August 2025
Department of Psychiatry, Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, 215131 Suzhou, Jiangsu, China.
Background: Schizophrenia (SCZ) is a common, chronic, severe mental disorder that is often accompanied by dyslipidemia and linked to decreased life expectancy. The prevalence of dyslipidemia among initial-treatment and drug-naïve (ITDN) patients with SCZ and the correlates influencing its occurrence and severity were determined in this study.
Methods: Demographic and clinical data including blood pressure, blood cell count, renal function, lipid profile, fasting glucose level, and thyroid function were collected from the 668 patients with ITDN SCZ included in this study.